AtriCure (NASDAQ:ATRC) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Key Points

• Canaccord Genuity raised its AtriCure price target to $67 from $55 and maintained a Buy rating, implying about 2.2% upside from the share price cited in the report.
• AtriCure beat third-quarter expectations, reporting EPS of $0.17 versus analysts’ estimate of a $0.06 loss, and revenue of $154.45 million versus $151.05 million expected.
• Analyst views remain mixed: MarketBeat reported a consensus Hold rating and an average target of $61.80, while several firms raised targets and UBS downgraded the stock to Sell.

AtriCure (NASDAQ:ATRC - Get Free Report) had its target price increased by equities research analysts at Canaccord Genuity Group from $55.00 to $67.00 in a report released on Wednesday, Benzinga reports. The firm currently has a "buy" rating on the medical device company's stock. Canaccord Genuity Group's price target suggests a potential upside of 2.24% from the company's current price.

ATRC has been the subject of several other reports. UBS Group lowered AtriCure from a "buy" rating to a "sell" rating in a research report on Wednesday, October 21st. Stifel Nicolaus set a $65.00 price target on AtriCure in a research note on Thursday, September 17th. Citizens Jmp increased their price target on AtriCure from $52.00 to $68.00 and gave the stock a "market outperform" rating in a report on Wednesday, October 21st. Piper Sandler reissued an "overweight" rating and set a $70.00 price objective (up from $60.00) on shares of AtriCure in a research report on Wednesday. Finally, Weiss Ratings upgraded shares of AtriCure from a "hold (c-)" rating to a "hold (c)" rating in a report on Thursday, October 8th. Six equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $61.80.

AtriCure Price Performance

ATRC traded up $5.12 during trading on Wednesday, reaching $65.53. The company's stock had a trading volume of 1,335,550 shares, compared to its average volume of 874,695. The company has a market cap of $3.33 billion, a price-to-earnings ratio of 312.06 and a beta of 1.23. The firm has a fifty day simple moving average of $56.03 and a two-hundred day simple moving average of $38.40. AtriCure has a 1 year low of $25.36 and a 1 year high of $66.02. The company has a quick ratio of 3.19, a current ratio of 4.22 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.23. The firm had revenue of $154.45 million during the quarter, compared to analysts' expectations of $151.05 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. As a group, analysts anticipate that AtriCure will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other news, Director Regina Groves sold 5,313 shares of the stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the sale, the director owned 34,546 shares of the company's stock, valued at approximately $1,873,084.12. This represents a 13.33% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Karl Dahlquist sold 9,370 shares of the firm's stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the transaction, the insider directly owned 87,319 shares of the company's stock, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,622 shares of company stock worth $1,626,003 over the last three months. Company insiders own 4.00% of the company's stock.

Hedge Funds Weigh In On AtriCure

Institutional investors have recently modified their holdings of the business. Harbor Investment Advisory LLC acquired a new stake in shares of AtriCure in the second quarter valued at $40,000. Allworth Financial LP acquired a new position in AtriCure during the 2nd quarter worth $43,000. Integrated Wealth Concepts LLC acquired a new position in AtriCure during the 2nd quarter worth $46,000. Fifth Third Bancorp purchased a new stake in AtriCure during the 1st quarter worth about $51,000. Finally, Global Retirement Partners LLC purchased a new stake in AtriCure during the 2nd quarter worth about $52,000. Institutional investors and hedge funds own 99.11% of the company's stock.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported third-quarter earnings of $0.17 per share and revenue of $154.45 million, beating analyst estimates. The earnings result also improved from a loss per share in the year-ago quarter. AtriCure Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: The company expects 2026 revenue of $606 million to $610 million, roughly in line with consensus, and projects adjusted EBITDA of $91 million to $94 million. It also aims to complete BoxX-NoAF enrollment by year-end. AtriCure Projects 2026 EBITDA and Targets Enrollment Completion
• Positive Sentiment: Analyst revisions added support: Piper Sandler reaffirmed its overweight rating and raised its target to $70 from $60; Needham lifted its target to $70 from $64 and maintained a buy rating. BTIG also raised its target to $70. Analysts Boost Forecasts After Q3 Results
• Negative Sentiment: JPMorgan raised its price target substantially, from $36 to $62, but kept a neutral rating; the new target is below the current share price, signaling limited upside at that level. JPMorgan Analyst Recommendation

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.